Abiraterone Acetate in Combination With Tildrakizumab
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the side effects and safety of a combination of the
anti-IL23 targeting monoclonal antibody tildrakizumab in combination with abiraterone acetate
in men with metastatic castration resistant prostate cancer and to determine the most
appropriate dose of this combination. In the Phase I part of this study small groups of
patients will be treated with increasing doses of tildrakizumab in combination with a fixed
dose of abiraterone acetate (500mg once daily). Once Phase I has been completed the
combination with the optimum safety and pharmacokinetic/pharmacodynamic profile will be taken
forward to the Phase II part of the study. The Phase II part of the study will evaluate the
optimized dose/schedule identified in Phase I of the study in patients with metastatic
castration resistant prostate cancer.